Docking, Synthesis, and in vitro Evaluation of Antimitotic Estrone Analogs

Chemical Biology and Drug Design

Volumn 77, Issue 3, 2011, Pages 173-181

  Stander, Andre ^a   Joubert, Fourie ^a   Joubert, Annie ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Biological screening; Mechanism based drug design; Virtual screening

Indexed keywords

2 ETHYL 3 O SULPHAMOY LESTRA 1,3,5(10), 15 TETRAEN 3 OL 17 ONE ESTRONEM; 2 ETHYL 3 O SULPHAMOYL ESTRA 1,3,5(10) 16 TETRAENE; 3,4 METHYLENEDIOXYAMPHETAMINE; ANTIMITOTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; COLCHICINE; CRYSTAL VIOLET; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FRACTIONATION; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG SCREENING; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS RATE; MOLECULAR DOCKING; PRIORITY JOURNAL; SPECTROPHOTOMETRY; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; ANTIMITOTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CELL DIVISION; CELL LINE, TUMOR; COLCHICINE; COMPUTER SIMULATION; DRUG DESIGN; ESTRONE; FEMALE; G2 PHASE; HUMANS; SOFTWARE; TUBULIN;

EID: 79651470475     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01064.x     Document Type: Article

References (46)

1. Schmidt M., Bastians H. (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat;10:162-181.
2. Mollinedo F., Gajate C. (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis;8:413-450.
3. Zhou J., Giannakakou P. (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents;5:65-71.
4. Jordan M.A., Wilson L. (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer;4:253-265.
5. Kamath K., Okouneva T., Larson G., Panda D., Wilson L., Jordan M.A. (2006) 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther;5:2225-2233.
6. Cirla A., Mann J. (2003) Combretastatins: from natural products to drug discovery. Nat Prod Rep;20:558-564.
7. Mooberry S.L. (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat;6:355-361.
8. D'Amato R.J., Lin C.M., Flynn E., Folkman J., Hamel E. (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A;91:3964-3968.
9. Newman S.P., Ireson C.R., Tutill H.J., Day J.M., Parsons M.F., Leese M.P., Potter B.V., Reed M.J., Purohit A. (2006) The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res;66:324-330.
10. Elger W., Schwarz S., Hedden A., Reddersen G., Schneider B. (1995) Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol;55:395-403.
11. Leese M.P., Leblond B., Smith A., Newman S.P., Di Fiore A., De Simone G., Supuran C.T., Purohit A., Reed M.J., Potter B.V. (2006) 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem;49:7683-7696.
12. Ho Y.T., Purohit A., Vicker N., Newman S.P., Robinson J.J., Leese M.P., Ganeshapillai D., Woo L.W., Potter B.V., Reed M.J. (2003) Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun;305:909-914.
13. Supuran C.T., Scozzafava A. (2007) Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem;15:4336-4350.
14. Stubbs M., McSheehy P.M., Griffiths J.R., Bashford C.L. (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today;6:15-19.
15. Pastorekova S., Ratcliffe P.J., Pastorek J. (2008) Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int;101(Suppl. 4):8-15.
16. Svastova E., Hulikova A., Rafajova M., Zat'ovicova M., Gibadulinova A., Casini A., Cecchi A., Scozzafava A., Supuran C.T., Pastorek J., Pastorekova S. (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett;577:439-445.
17. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. (2004) UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem;25:1605-1612.
18. Word J.M., Lovell S.C., Richardson J.S., Richardson D.C. (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol;285:1735-1747.
19. Pedretti A., Villa L., Vistoli G. (2004) VEGA--an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput Aided Mol Des;18:167-173.
20. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem;30:2785-2791.
21. Krishnamurthy V.M., Kaufman G.K., Urbach A.R., Gitlin I., Gudiksen K.L., Weibel D.B., Whitesides G.M. (2008) Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev;108:946-1051.
22. Tuccinardi T., Nuti E., Ortore G., Supuran C.T., Rossello A., Martinelli A. (2007) Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study. J Chem Inf Model;47:515-525.
23. Totrov M., Abagyan R. (2008) Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol;18:178-184.
24. Genis C., Sippel K.H., Case N., Cao W., Avvaru B.S., Tartaglia L.J., Govindasamy L., Tu C., Agbandje-McKenna M., Silverman D.N., Rosser C.J., McKenna R. (2009) Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry;48:1322-1331.
25. Wang J., Wang W., Kollman P.A., Case D.A. (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model;25:247-260.
26. Yang L., Tan C.H., Hsieh M.J., Wang J., Duan Y., Cieplak P., Caldwell J., Kollman P.A., Luo R. (2006) New-generation amber united-atom force field. J Phys Chem B;110:13166-13176.
27. Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. (2004) Development and testing of a general amber force field. J Comput Chem;25:1157-1174.
28. Cushman M., He H.M., Katzenellenbogen J.A., Lin C.M., Hamel E. (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem;38:2041-2049.
29. Leese M.P., Newman S.P., Purohit A., Reed M.J., Potter B.V. (2004) 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorg Med Chem Lett;14:3135-3138.
30. Edsall A.B., Mohanakrishnan A.K., Yang D., Fanwick P.E., Hamel E., Hanson A.D., Agoston G.E., Cushman M. (2004) Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization. J Med Chem;47:5126-5139.
31. Tinley T.L., Leal R.M., Randall-Hlubek D.A., Cessac J.W., Wilkens L.R., Rao P.N., Mooberry S.L. (2003) Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res;63:1538-1549.
32. Zhou Q., Gustafson D., Nallapareddy S., Diab S., Leong S., Lewis K., Gore L., Messersmith W.A., Treston A.M., Eckhardt S.G., Sidor C., Camidge D.R. (2010) A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs; in print
33. LaVallee T.M., Burke P.A., Swartz G.M., Hamel E., Agoston G.E., Shah J., Suwandi L., Hanson A.D., Fogler W.E., Sidor C.F., Treston A.M. (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther;7:1472-1482.
34. Utsumi T., Leese M.P., Chander S.K., Gaukroger K., Purohit A., Newman S.P., Potter B.V., Reed M.J. (2005) The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol;94:219-227.
35. Appel R., Berger G. (1958) Hydrazinsulfonsäure-amide, I. Über das Hydrazodisulfamid. Chem Berichte;91:1339-1341.
36. Gillies R.J., Didier N., Denton M. (1986) Determination of cell number in monolayer cultures. Anal Biochem;159:109-113.
37. Kueng W., Silber E., Eppenberger U. (1989) Quantification of cells cultured on 96-well plates. Anal Biochem;182:16-19.
38. Grever M.R., Schepartz S.A., Chabner B.A. (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol;19:622-638.
39. Purohit A., Vernon K.A., Hummelinck A.E., Woo L.W., Hejaz H.A., Potter B.V., Reed M.J. (1998) The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. The Journal of steroid biochemistry and molecular biology;64:269-275.
40. Patton T.L., Dmochowski L. (1963) Estrogens. V. Studies on the relationship of estrogenic activity and molecular structure. Arch Biochem Biophys;101:181-185.
41. Elger W., Barth A., Hedden A., Reddersen G., Ritter P., Schneider B., Zuchner J., Krahl E., Muller K., Oettel M., Schwarz S. (2001) Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod Fertil Dev;13:297-305.
42. Berry J.M., Huebner E., Butler M. (1996) The crystal violet nuclei staining technique leads to anomalous results in monitoring mammalian cell cultures. Cytotechnology;21:73-80.
43. Seegers J.C., Aveling M.L., Van Aswegen C.H., Cross M., Koch F., Joubert W.S. (1989) The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. Journal of steroid biochemistry;32:797-809.
44. Joubert A., Marais S. (2007) In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells. Cell Biochem Funct;25:357-362.
45. Van Zijl C., Lottering M.L., Steffens F., Joubert A. (2008) In vitro effects of 2-methoxyestradiol on MCF-12A and MCF-7 cell growth, morphology and mitotic spindle formation. Cell Biochem Funct;26:632-642.
46. Li Y., Wang H., Oosterwijk E., Tu C., Shiverick K.T., Silverman D.N., Frost S.C. (2009) Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Invest;27:613-623.